Literature DB >> 8903494

Tumour marker detection in oesophageal carcinoma.

K Mealy1, J Feely, I Reid, J McSweeney, T Walsh, T P Hennessy.   

Abstract

Levels of the tumour markers CEA, CA 19-9, CA 125 and SCC were measured in 58 patients presenting with oesophageal carcinoma and compared with levels in patients with benign oesophageal disease and levels in normal volunteers. CEA and CA 19-9 were significantly increased in the patients with oesophageal cancer, however, individual sensitivity for CEA, CA 19-9, CA 125 and SCC was only 28, 34, 10, and 32%, respectively. The combined sensitivity of all markers was 64% and specificity was 80%. There was no difference in combined tumour marker sensitivity between squamous or adenocarcinomas of the oesophagus. No consistent change in marker levels occurred with treatment, and tumour marker levels could not be significantly correlated with stage of disease or short-term survival. These results indicate that tumour marker sensitivity is too low for oesophageal cancer screening and has poor prognostic significance in those undergoing treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8903494     DOI: 10.1016/s0748-7983(96)92998-4

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  20 in total

1.  Enhanced Expression of Fibroblast Growth Factor Receptor 3 IIIc Promotes Human Esophageal Carcinoma Cell Proliferation.

Authors:  Nobuhiro Ueno; Akio Shimizu; Michiyuki Kanai; Yugo Iwaya; Shugo Ueda; Jun Nakayama; Misuzu Kurokawa Seo
Journal:  J Histochem Cytochem       Date:  2015-10-20       Impact factor: 2.479

Review 2.  Oesophageal cancer--an overview.

Authors:  Michael Schweigert; Attila Dubecz; Hubert J Stein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

3.  Autoantibodies against MMP-7 as a novel diagnostic biomarker in esophageal squamous cell carcinoma.

Authors:  Jing-Hua Zhou; Bin Zhang; Kemp H Kernstine; Li Zhong
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

Review 4.  Alpha-fetoprotein-producing esophageal adenocarcinoma: a mimicker of hepatocellular carcinoma.

Authors:  Jeremy Wang; Wendy Liu; Keyur Parikh; Anthony Benjamin Post
Journal:  Clin J Gastroenterol       Date:  2016-12-19

5.  Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma.

Authors:  Jun Dong; Bo-hang Zeng; Li-hua Xu; Jun-ye Wang; Man-zhi Li; Mu-sheng Zeng; Wan-li Liu
Journal:  J Transl Med       Date:  2010-09-03       Impact factor: 5.531

6.  Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma.

Authors:  Xun Cao; Lin Zhang; Gui-Rong Feng; Juan Yang; Ruo-Yan Wang; Jun Li; Xiao-Min Zheng; Yu-Jing Han
Journal:  J Transl Med       Date:  2012-09-21       Impact factor: 5.531

7.  Detection of lymph node metastasis of oesophageal cancer by RT-nested PCR for SCC antigen gene mRNA.

Authors:  M Kano; Y Shimada; J Kaganoi; T Sakurai; Z Li; F Sato; G Watanabe; M Imamura
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

8.  Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis).

Authors:  Bhawna Bagaria; Sadhna Sood; Rameshwaram Sharma; Soniya Lalwani
Journal:  Cancer Biol Med       Date:  2013-09       Impact factor: 4.248

9.  Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma.

Authors:  Yi-Wei Xu; Yu-Hui Peng; Bo Chen; Zhi-Yong Wu; Jian-Yi Wu; Jin-Hui Shen; Chun-Peng Zheng; Shao-Hong Wang; Hai-Peng Guo; En-Min Li; Li-Yan Xu
Journal:  Am J Gastroenterol       Date:  2013-12-03       Impact factor: 10.864

10.  Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma.

Authors:  Xin Zheng; Shan Xing; Xiao-Min Liu; Wen Liu; Dan Liu; Pei-Dong Chi; Hao Chen; Shu-Qin Dai; Qian Zhong; Mu-Sheng Zeng; Wan-Li Liu
Journal:  BMC Cancer       Date:  2014-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.